Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without Birinapant in Higher-Risk MDS or CMML
2014-001719-37Phase 2Terminated
- Sponsor
- TetraLogic Pharmaceuticals
- Start
- Jun 2014
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of birinapant in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by TetraLogic Pharmaceuticals. Primary endpoint: Response rate (CR + PR) by modified IWG criteria for MDS. Started Jun 2014; status: terminated.
02
Drugs
birinapant
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2014-001719-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001719-37.